Curis stock: Q3 update brings 86% response rate in PCNSL study

Published on 11/13/2026 at 22:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Curis stock traded at 0.40 euros on Lang & Schwarz late Friday. Curis reported clinical progress and a third-quarter net loss.

Clinical Progress And Cash Runway

Curis reported updated emavusertib response data in relapsed or refractory primary central nervous system lymphoma.
The company expects initial data from its chronic lymphocytic leukemia study in December 2026.
Curis reported a third-quarter net loss of 8.1 million US dollars and cash of 5.0 million US dollars at September 30, 2026.

CRIS, US2312694084, Illustration mit AI erstellt.

On Thursday, November 12, 2026, Curis reported its third-quarter financial and operating results alongside an update on emavusertib. The details were carried by BioSpace in a report reproducing the company release.

Clinical Data Drive The Update

The release cited July 1, 2026 data from the TakeAim Lymphoma study in relapsed or refractory primary central nervous system lymphoma. The objective response rate was 86 percent among BTK-inhibitor-naive patients, with six of seven patients responding, and 26 percent among BTK-inhibitor-experienced patients, with 10 of 39 responding.

Curis is also enrolling patients in the TakeAim CLL study, which combines emavusertib with zanubrutinib. The company said 12 patients had been enrolled and that initial data are expected in December 2026.

Loss Widens As Revenue Falls

Curis reported a third-quarter net loss of 8.1 million US dollars, or 1.94 US dollars per share, compared with a 7.7 million US dollar loss in the same quarter of 2025. Revenue was zero after the company sold its Erivedge royalties in the fourth quarter of 2025.

For the first nine months of 2026, Curis reported a net loss of 40.9 million US dollars. Cash and cash equivalents totaled 5.0 million US dollars at September 30, and management said the October private placement should extend funding into the first quarter of 2027.